- Home
- PTGX vs AMPH Comparison
PTGX vs AMPH Comparison
Compare PTGX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AMPH
- Stock Information
- Founded
- PTGX 2006
- AMPH 1996
- Country
- PTGX United States
- AMPH United States
- Employees
- PTGX N/A
- AMPH N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AMPH Health Care
- Exchange
- PTGX Nasdaq
- AMPH Nasdaq
- Market Cap
- PTGX 3.3B
- AMPH 1.1B
- IPO Year
- PTGX 2016
- AMPH 2014
- Fundamental
- Price
- PTGX $49.87
- AMPH $22.86
- Analyst Decision
- PTGX Strong Buy
- AMPH Hold
- Analyst Count
- PTGX 9
- AMPH 5
- Target Price
- PTGX $67.11
- AMPH $38.00
- AVG Volume (30 Days)
- PTGX 1.0M
- AMPH 494.7K
- Earning Date
- PTGX 08-05-2025
- AMPH 08-06-2025
- Dividend Yield
- PTGX N/A
- AMPH N/A
- EPS Growth
- PTGX N/A
- AMPH N/A
- EPS
- PTGX 0.86
- AMPH 2.77
- Revenue
- PTGX $207,801,000.00
- AMPH $730,659,000.00
- Revenue This Year
- PTGX N/A
- AMPH $0.67
- Revenue Next Year
- PTGX $47.15
- AMPH $5.18
- P/E Ratio
- PTGX $57.82
- AMPH $8.36
- Revenue Growth
- PTGX N/A
- AMPH 8.05
- 52 Week Low
- PTGX $32.50
- AMPH $22.64
- 52 Week High
- PTGX $60.60
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- PTGX 41.97
- AMPH 34.73
- Support Level
- PTGX $49.86
- AMPH $22.81
- Resistance Level
- PTGX $57.24
- AMPH $23.77
- Average True Range (ATR)
- PTGX 2.08
- AMPH 0.77
- MACD
- PTGX -0.86
- AMPH -0.21
- Stochastic Oscillator
- PTGX 4.66
- AMPH 1.84
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.